Category 2

The ATTR meeting 2025 is the premier global event dedicated to the latest advancements in transthyretin amyloidosis (ATTR) research, treatment, and patient care. Scheduled for September 2025, this landmark event…

On November 29, 2024, the Amyloidosis Alliance officially launched Amylife: amyloidosis survey, a groundbreaking global survey designed to explore the daily challenges and needs of patients living with amyloidosis and…

🌍🌟 On October 26, 2024, we invite you to take part in a special World Amyloidosis Day event—an international live multiplex broadcast featuring leading amyloidosis organizations and experts from different…

On October 26, 2024, the global amyloidosis community will come together for the 4th World Amyloidosis Day, a pivotal event aimed at raising awareness, educating the public, and fostering support for those affected by amyloidosis. Organized by the Amyloidosis Alliance, this year’s event will see a series of activities and campaigns across multiple countries…

The Amyloidosis Alliance is thrilled to announce the inaugural Amyloidosis AL Congress, set to take place on July 5th and 6th in Belgium.
The Amyloidosis AL Congress is designed to foster an environment of learning and collaboration. It will be available online and on site.

From Sunday, May 26 to Thursday, May 30, 2024, the city of Rochester, MN hosted the XIX International Symposium on Amyloidosis. Organized in collaboration with the International Society of Amyloidosis (ISA) Board and esteemed members of the Mayo Clinic, the symposium delivered a dynamic and engaging scientific program.

On May 17th, 2024, the Centre Hospitalier Universitaire Vaudois (CHUV) and the Hôpitaux Universitaires de Genève (HUG) hosted a pivotal afternoon dedicated to amyloidosis. This event was more than just…

Did you know that the symptoms of amyloidosis can often mimic those of other conditions, leading to misdiagnosis and delayed treatment? Amyloidosis is a rare disease characterized by the buildup…

A new study published about Hereditary Transthyretin Amyloid Polyneuropathy sheds light on the effectiveness of treatments for FAP